idea-017 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the user. The adult with chronic respiratory failure consequent to COPD who would sleep under a high-intensity mask and, on prescribed nights, wear a heated sensor at the ear or chest; the spouse or caregiver who makes that happen at night; and the pulmonologist or sleep physician who would have to look at a bedroom CO2 trace and change a setting because of it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-017.md: the number is the claim's position in its ## Claims list, and the tag is the one that claim carries there, copied and never adjusted. A no-claim marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
What changed since the last build. The Verifier's 2026-09-29 pass put numbers on the supply side — the E0471 (a HCPCS code for durable medical equipment) descriptor, the national E0471 rental volume, the monthly allowable — and moved every earlier deck write-back from unverified to unconfirmed. It also surfaced two facts that cut at this lens directly: NCD 240.9 (a Medicare national coverage determination number) does not require an attended titration, and the 2020 ATS guideline suggests not titrating NIV (non-invasive ventilation) in the sleep lab. So the question a prescriber is asked is no longer "home trace instead of a lab study" but "a home trace instead of what I already do at home". This build restates the prescriber condition that way; the new form is claim 41unverified.
Would have to be true: A findable population of US adults would have to be in the specific window the device is built for — chronic respiratory failure consequent to COPD, awake PaCO2 at or above the NCD (national coverage determination)'s entry threshold, typically in the weeks after a hospitalised exacerbation — and their course without home NIV would have to be bad enough that they would accept a nightly mask to change it.
Where it stands: The clinical stakes for this window are the best-anchored user-side fact in the file: in HOT-HMV, adding home NIV to home oxygen after a life-threatening exacerbation extended median admission-free survival to 4.3 months versus 1.4 months, with 12-month mortality not significantly different (28.1% versus 32.2%) claim 15verified. The same claim's note records that the trial was UK-conducted and carries no US regulatory or reimbursement weight. The entry threshold is the NCD's: "PaCO2 ≥ 52 mmHg (millimetres of mercury) by arterial blood gas during awake hours", quoted in the note on claim 30unconfirmed, under an NCD whose existence and population are confirmed claim 1verified. How many US patients sit in the window is not established: the ~16 million diagnosed-COPD base has no primary table attached claim 12unconfirmed, and the share meeting NCD criteria is an unsourced Generator estimate claim 11unconfirmed, whose note warns that HOT-HMV's 2,021-screened-for-124-eligible figure is recruitment, not prevalence.
What would settle it: A human-attached CDC/BRFSS or NHIS prevalence table for diagnosed COPD, plus a published estimate of chronic hypercapnic respiratory failure within it. No connector reaches either; market is unverifiable by design.
If it's false: The TAM (total addressable market) factor loses its population leg (the viability deck's Slide 3 fails on the same number), and a device aimed at a window too narrow to find patients in has no user.
Would have to be true: The patient would have to sleep nightly under a mask at a pressure of at least the NCD's high-intensity floor with a fixed back-up rate, add a heated tcCO2 (transcutaneous carbon dioxide) sensor on prescribed nights, and keep using the ventilator at the level Medicare audits for continued payment — without refusing or dropping out because of the sensor.
Where it stands: The pressure the patient must tolerate is lower than the file first said. The claim that the coverage envelope requires IPAP above 20 cm H2O is claim 5refuted — the NCD's own sentence reads "a minimum IPAP ≥ 15 cm H2O and backup respiratory rate of at least 14 breaths per minute". The 20-plus figure is trial practice: HOT-HMV's median setting was IPAP 24 cm H2O (IQR 22-26) claim 15verified. Whether patients tolerate and adhere in ordinary practice, and apply the sensor correctly, is an assumption with no primary research behind it claim 29unconfirmed; its note records the continued-coverage bar — use "at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period", re-established at 6 months and again at 7-12 months. Whether the sensor itself raises refusal or discontinuation over plain bi-level NIV had nothing behind it before this build and is now on record claim 42unverified. Unaided sensor application is Slide 6's subject claim 33unconfirmed.
What would settle it: A prospective observation in ordinary US practice, not a trial: enrolled patients tracked against the NCD's 4-hour/70%-of-days threshold over 30 days, with sensor-nights, sensor refusals and discontinuations logged separately from ventilator-nights, against a comparison group on bi-level NIV without the sensor. Primary research; a human has to commission it.
If it's false: Therapy stops being paid before the capped-rental period ends — a desirability failure that is also the viability deck's persistence condition (its Slide 3, claim 36unconfirmed). The refutation of claim 5refuted is the one piece of room here: the tolerability question can be asked at IPAP ≥ 15 rather than above 20.
Would have to be true: A US pulmonologist or sleep physician who already initiates home NIV would have to change a patient's ventilation settings because of a home overnight tcCO2 trace in cases where, without it, they would have left the settings alone or adjusted them only on a daytime arterial blood gas — and would have to prescribe a new entrant's device over the ResMed or Philips platform already in their clinic to get that trace.
Where it stands: Nothing in the file shows prescribers want the trace, and the file's own evidence has moved the comparator. The earlier form of this condition — practitioners accepting a home tcCO2 recording in place of an attended in-laboratory titration — is an assumption with no primary research claim 30unconfirmed, and its note records that NCD 240.9 does not require an attended titration and contains the word "transcutaneous" nowhere; every CO2 figure it specifies is arterial. The 2020 ATS guideline, carried as a pointer rather than a verification, suggests "not using an in-laboratory overnight polysomnogram to titrate NIV" and suggests "targeted normalization of PaCO2" — an arterial target claim 32unconfirmed. So the real comparator is what prescribers already do at home, and whether a tcCO2 trace changes their decisions against that comparator had nothing behind it before this build claim 41unverified. The brand switch is a separate assumption, unverifiable by the adoption connector claim 27unconfirmed; both incumbents hold current clearances (K161492 (an FDA 510(k) clearance number), K102465). The DME (durable medical equipment) supplier's consent is a money question and is stated on the viability deck's Slides 1 and 7 (claims 28 and 43), not repeated here. Medicare has already said yes to the therapy category claim 1verified.
What would settle it: Structured interviews with twenty US pulmonologists and sleep physicians who currently order home NIV for hypercapnic COPD: how they set and adjust settings today, how often they would want an overnight CO2 trace, and — shown a sample trace — whether they would sign a settings change off it. Add a human retrieval of LCD (local coverage determination) L33800 (a Medicare local coverage determination number) and article A52517, where documentation requirements would live and which no connector here reads claim 6unconfirmed.
If it's false: The device records a number nobody acts on; the novel half of the product has no user, and what remains is a bi-level ventilator competing with two incumbents. This is this deck's load-bearing condition — see Slide 8.
Would have to be true: The patient would have to accept the Medicare Part B (Medicare Part B) cost share on a capped-rental allowable plus any non-covered charge for the sensor and its consumables, and the non-money costs — a mask and fixed back-up rate that override their own breathing, a heated sensor on the skin overnight, a ventilator in a shared bedroom — without abandoning therapy.
Where it stands: The base of the money half now has a number and the patient's share of it still does not. The July 2026 DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee schedule carries E0471 as a capped-rental RR line at $324.35-$347.40 per rental month non-rural and $520.32-$579.71 rural — Medicare allowed amounts with the beneficiary's coinsurance inside them claim 10unconfirmed (the tag reflects that claim's revenue-per-patient arithmetic, which the regulation contradicts, not the published allowable). The coinsurance percentage itself was not looked up, and nothing in the file carries it; whether patients accept the cost share plus any sensor charge is an assumption claim 31unconfirmed. Whether the sensor is separately payable at all is stated on the viability deck's Slide 2 claim 34unconfirmed. The non-money half is on record only as the refusal/discontinuation condition from Slide 2 claim 42unverified.
What would settle it: A human look-up of the Part B DME coinsurance rule gives the monthly patient share against the allowables above — the cheapest number on this deck. What the patient gives up needs interviews in the post-exacerbation population, which is primary research.
If it's false: Patients abandon at the first invoice rather than the first mask, and the adherence bar on Slide 2 is never reached.
Would have to be true: The evidence a prescriber actually uses — a US specialty-society guideline, not a clearance — would have to point at home NIV for chronic hypercapnic COPD and be compatible with titrating it against a transcutaneous rather than an arterial CO2 target.
Where it stands: Half of this now has a pointer and the other half points the wrong way. The guideline exists as a pointer: "An Official American Thoracic Society Clinical Practice Guideline" (2020, PMID (PubMed identifier) 32795139) suggests nocturnal NIV for chronic stable hypercapnic COPD as a conditional recommendation at moderate certainty — read off a literature scan that carries no tag of its own, so the claim stays claim 32unconfirmed, and whether prescribers cite it is unresearched. The same guideline's titration recommendation targets PaCO2, which is arterial. The trial result is confirmed claim 15verified, but that HOT-HMV titrated to overnight transcutaneous CO2 is not anchored — the full structured abstract says nothing about tcCO2 or the titration target, and the file calls this a real source silence claim 16unconfirmed. Whether home tcCO2 can stand in for PaCO2 as a target is the feasibility deck's question claim 37unconfirmed.
What would settle it: The JAMA methods section for PMID 28528348 (free to a human, paywalled to every connector here) for the trial's titration target; a human read of the full ATS guideline text for what it says about transcutaneous monitoring.
If it's false: The prescriber on Slide 3 is being asked to titrate against a signal their own guideline does not name, on the strength of a UK trial whose titration protocol nobody here has read.
Would have to be true: In the first ten real patients, the patient or caregiver would have to place the sensor unaided on a prescribed night and produce a trace the practitioner calls interpretable, and the practitioner would have to change a setting off it that they would not otherwise have changed. The falsifying observations are specific: unreadable traces, sensors found detached in the morning, patients declining sensor nights, or practitioners who read a good trace and change nothing.
Where it stands: Unaided home application has nothing behind it; the one cleared tcCO2 system with home language, SenTec K071672, is indicated for home use "if under clinical supervision", which is the opposite of unaided claim 33unconfirmed, and that cleared indication sits inside a claim whose tag is carried as it stands claim 24unconfirmed. The "would not otherwise have changed" half is Slide 3's condition claim 41unverified.
What would settle it: A ten-patient in-home usability study run by a human in the target population, recording first-night placement success, the fraction of traces the practitioner calls interpretable, and the fraction producing a settings change the practitioner says they would not otherwise have made. It overlaps the human-factors work the feasibility deck's Slide 6 names.
If it's false: The recording channel produces no usable data outside a clinic, or usable data nobody acts on — either way the product reduces to a bi-level ventilator.
Every condition above with nothing verified behind it — the no-claim markers, plus the unverified claims this deck itself put on record. Read this slide first.
One reference on this deck is refuted, and it helps rather than hurts: the NCD's high-intensity pressure floor is IPAP ≥ 15 cm H2O, not above 20 claim 5refuted.
Twelve of this deck's conditions rest on unverified or unconfirmed claims; none rests on [no claim], because this build wrote its two unbacked conditions back first. The only two verified claims the deck leans on (claims 1 and 15) are about a CMS (Centers for Medicare & Medicaid Services) instrument and what happened to 124 UK trial patients — not about what a US patient or prescriber would choose. The rubric scores no factor for whether a user wants the thing, so this shape is expected and is information about the pipeline as much as about this idea.
If only one thing from this chair could be checked: whether US pulmonologists and sleep physicians who already initiate home NIV for hypercapnic COPD would change ventilation settings on the basis of a home overnight transcutaneous CO2 recording in cases where, without it, they would leave the settings unchanged or adjust them only on a daytime arterial blood gas claim 41unverified.
This one rather than the others because every other user-side condition sits downstream of it: if the prescriber does not act on the trace, sensor usability and sensor-night adherence do not matter. It is also where the file's own evidence has moved: the NCD requires no attended titration and names only arterial CO2, and the ATS guideline suggests against lab titration and targets PaCO2 — so the displaced event is not a lab study, and the device has to beat what prescribers already do at home.
Naming it is not a recommendation, a gate, or a kill. It is the answer to "check what first."
_shared/plain-language.md